150438-33-8

Upstream product

• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 150438-32-7 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-propyl-1-<<2'-<1-(triphenylmethyl)-1H-tetrazol-5-yl><1,1'-biphenyl>-4-yl>methyl>-1H-imidazole-5-carboxaldehyde 
• 150537-90-9 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-propyl-1-[[2'-(N-triphenylmethyl-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-imidazole-5-carboxaldehyde 
• 150438-29-2 methyl 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-propyl-1H-imidazole-4-carboxylate 
• 150438-30-5 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-propyl-1H-imidazole-4-methanol 
• 150438-31-6 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-propyl-1H-imidazole-4-carboxaldehyde 
• 150437-96-0 methyl 4-amino-2-propyl-1H-imidazole-5-carboxylate 
• 150437-95-9 methyl N-(N'-cyanobutyrimidoyl)glycinate 

Downstream Products

• 150438-34-9 methyl (E)-3-(4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl}-1H-imidazol-5-yl)-2-propenoate 

Relevant academic research and scientific papers

4-(1H-PYRROL-1-YL)IMIDAZOLES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY

Novel substituted 4-(1-H-pyrrol-1-yl)imidazoles are disclosed as well as methods of preparing them, pharmaceutical compositions containing them, and methods of using them. Novel intermediates useful in the preparation of the compounds of the invention are also disclosed and synthetic methods for preparing the novel intermediates. The compounds are useful as antagonists of angiotensin II and thus are useful in the control of hypertension, hyperaldosteronism, congestive heart failure, glaucoma, vascular smooth muscle proliferation associated with atherosclerosis, and with postsurgical vascular restenosis.

Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: Profile of 2-propyl-1-[[2'-(tetrazol-5-yl)-[1,1'-biphenyl]-4- yl]-methyl]-4-[2-(trifluoroace

A novel series of nonpeptide angiotensin II (AII) receptor antagonists containing a 1H-pyrrol-1-yl moiety at the 4-position of the imidazole have been developed. The pyrrole group occupies the same lipophilic pocket at the receptor as the chloro group in